Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of inhaled Trasylol (aprotinin) in moderate COVID-19
2020-002434-33Phase 3Terminated
- Sponsor
- Hospital General Universitario Ciudad Real
- Start
- Feb 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of aprotinin in coronavirus pneumonia (2 arms), sponsored by Hospital General Universitario Ciudad Real. Primary endpoint: Ingreso en UCI. Started Feb 2022; status: terminated.
02
Drugs
aprotinin
03
Conditions
coronavirus pneumonia
Beyond the preview
Go deeper on 2020-002434-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002434-33.